Pharmacokinetics of theanine enantiomers in rats

被引:69
|
作者
Desai, MJ
Gill, MS
Hsu, WH
Armstrong, DW
机构
[1] Iowa State Univ, Dept Chem, Ames, IA 50011 USA
[2] Iowa State Univ, Dept Biomed Sci, Ames, IA 50011 USA
关键词
pharmacokinetics; theanine; chiral; LGMS; absorption; metabolism; excretion;
D O I
10.1002/chir.20144
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Theanine, first discovered in tea, is a chiral nonproteinic amino acid that has been reported to have cardiovascular, neurological, and oncological effects. It is being considered as a therapeutic/medicinal agent and additive in consumer products. The present study evaluated the pharmacokinetics Of D-theanine, L-theanine, and D,L-theanine in plasma and urine using LGESUMS in rats after oral (p.o.) and intraperitoneal (i.p.) administration. Oral administration data indicated that gut absorption Of D-theanine was far less than that of L-theanine. However, after i.p. administration, plasma theanine concentrations of L- and D-theanine were similar. This indicated that D- and L-theanine may exhibit a competitive effect with respect to intestinal absorption. Regardless of the route of administration, p.o. or i.p., the presence of the other enantiomer always decreased theanine plasma concentrations, indicating D,L-theanine competition with respect to urinary reabsorption. Data on urinary concentrations of D-theanine suggested that the D-isomer may be eliminated with minimal metabolism. L-Theanine appeared to be preferentially reabsorbed and metabolized by the kidney while D-theanine was preferentially excreted. Clearly, the bioequivalencies of D,L-theanine and its enantiomers were found to be quite different from one another. Consequently, the efficacy of commercial theanine products containing D-theanine, L-theanine, or D,L-theanine may be quite different.
引用
收藏
页码:154 / 162
页数:9
相关论文
共 50 条
  • [31] PHARMACOKINETICS OF THE ENANTIOMERS OF VERAPAMIL IN THE DOG
    BAI, SA
    LANKFORD, SM
    JOHNSON, LM
    CHIRALITY, 1993, 5 (06) : 436 - 442
  • [32] Pharmacokinetics and metabolism of clausenamide enantiomers
    Zhu, Chuan-Jiang
    Zhang, Jun-Tian
    FASEB JOURNAL, 2014, 28 (01):
  • [33] HUMAN PHARMACOKINETICS OF BETAXOLOL ENANTIOMERS
    STAGNI, G
    DAVIS, PJ
    LUDDEN, TM
    JOURNAL OF PHARMACEUTICAL SCIENCES, 1991, 80 (04) : 321 - 324
  • [34] Pharmacokinetics of clinafloxacin enantiomers in humans
    Humphrey, GH
    Shapiro, MA
    Randinitis, EJ
    Guttendorf, RJ
    Brodfuehrer, JI
    JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 39 (11): : 1143 - 1150
  • [35] Clinical pharmacokinetics of fexofenadine enantiomers
    Miura, Masatomo
    Uno, Tsukasa
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2010, 6 (01) : 69 - 74
  • [36] THE PHARMACOKINETICS OF THE ENANTIOMERS OF MEXILETINE IN HUMANS
    IGWEMEZIE, L
    KERR, CR
    MCERLANE, KM
    XENOBIOTICA, 1989, 19 (06) : 677 - 682
  • [37] The pharmacokinetics of ethosuximide enantiomers in the rat
    Mifsud, J
    Collier, PS
    Millership, JS
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2001, 22 (02) : 83 - 89
  • [38] Pharmacokinetics of thiamylal enantiomers in humans
    Sueyasu, M
    Ikeda, T
    Taniyama, T
    Futugami, K
    Kataoka, Y
    Oishi, R
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 1997, 35 (03) : 128 - 132
  • [39] PHARMACOKINETICS OF IBUPROFEN ENANTIOMERS IN DOGS
    BECK, WS
    GEISSLINGER, G
    ENGLER, H
    BRUNE, K
    CHIRALITY, 1991, 3 (03) : 165 - 169
  • [40] IFOSFAMIDE ENANTIOMERS - PHARMACOKINETICS IN CHILDREN
    PRASAD, VK
    CORLETT, SA
    ABAASI, K
    HENEY, D
    LEWIS, I
    CHRYSTYN, H
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1994, 34 (05) : 447 - 449